The Oncology Institute, Inc. (NASDAQ:TOI) Major Shareholder Havencrest Healthcare Partners Sells 200,000 Shares

The Oncology Institute, Inc. (NASDAQ:TOIGet Rating) major shareholder Havencrest Healthcare Partners sold 200,000 shares of the business’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $4.50, for a total transaction of $900,000.00. Following the transaction, the insider now directly owns 14,733,544 shares of the company’s stock, valued at approximately $66,300,948. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Havencrest Healthcare Partners also recently made the following trade(s):

  • On Monday, September 19th, Havencrest Healthcare Partners sold 19,629 shares of Oncology Institute stock. The shares were sold at an average price of $4.33, for a total transaction of $84,993.57.
  • On Wednesday, September 14th, Havencrest Healthcare Partners sold 37,785 shares of Oncology Institute stock. The shares were sold at an average price of $4.99, for a total transaction of $188,547.15.
  • On Monday, September 12th, Havencrest Healthcare Partners sold 38,000 shares of Oncology Institute stock. The shares were sold at an average price of $5.52, for a total transaction of $209,760.00.
  • On Friday, September 9th, Havencrest Healthcare Partners sold 18,900 shares of Oncology Institute stock. The shares were sold at an average price of $5.80, for a total transaction of $109,620.00.
  • On Wednesday, September 7th, Havencrest Healthcare Partners sold 45,000 shares of Oncology Institute stock. The shares were sold at an average price of $6.04, for a total transaction of $271,800.00.
  • On Wednesday, August 31st, Havencrest Healthcare Partners sold 25,000 shares of Oncology Institute stock. The shares were sold at an average price of $6.36, for a total transaction of $159,000.00.
  • On Monday, August 29th, Havencrest Healthcare Partners sold 15,000 shares of Oncology Institute stock. The stock was sold at an average price of $6.14, for a total transaction of $92,100.00.
  • On Friday, August 26th, Havencrest Healthcare Partners sold 40,000 shares of Oncology Institute stock. The stock was sold at an average price of $6.03, for a total transaction of $241,200.00.
  • On Wednesday, August 24th, Havencrest Healthcare Partners sold 21,084 shares of Oncology Institute stock. The stock was sold at an average price of $6.37, for a total transaction of $134,305.08.
  • On Monday, August 22nd, Havencrest Healthcare Partners sold 35,500 shares of Oncology Institute stock. The stock was sold at an average price of $6.53, for a total transaction of $231,815.00.

Oncology Institute Trading Down 0.7 %

Shares of Oncology Institute stock opened at $4.49 on Tuesday. The company’s 50-day moving average price is $6.14 and its two-hundred day moving average price is $6.67. The Oncology Institute, Inc. has a 52 week low of $3.75 and a 52 week high of $12.66.

Oncology Institute (NASDAQ:TOIGet Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.06) EPS for the quarter. The business had revenue of $60.92 million for the quarter. As a group, analysts expect that The Oncology Institute, Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TOI shares. Guggenheim started coverage on shares of Oncology Institute in a report on Wednesday, September 14th. They issued a “buy” rating and a $7.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Oncology Institute in a research report on Monday, August 15th. They issued a “buy” rating and a $10.00 price target on the stock.

Institutional Trading of Oncology Institute

Several institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. acquired a new position in shares of Oncology Institute in the 2nd quarter valued at about $44,000. JPMorgan Chase & Co. increased its holdings in shares of Oncology Institute by 2,410.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,041 shares of the company’s stock valued at $51,000 after purchasing an additional 9,641 shares during the period. Bank of America Corp DE acquired a new position in shares of Oncology Institute in the 1st quarter valued at about $69,000. Rhumbline Advisers acquired a new position in shares of Oncology Institute in the 2nd quarter valued at about $114,000. Finally, Northern Trust Corp acquired a new position in shares of Oncology Institute in the 1st quarter valued at about $129,000. Institutional investors and hedge funds own 69.97% of the company’s stock.

Oncology Institute Company Profile

(Get Rating)

The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

Recommended Stories

Insider Buying and Selling by Quarter for Oncology Institute (NASDAQ:TOI)

Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.